Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $84,644.84 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 4,207 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $20.12, for a total value of $84,644.84. Following the completion of the sale, the insider now owns 85,236 shares of the company’s stock, valued at $1,714,948.32. The trade was a 4.70 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.76, for a total value of $8,254.40.
• On Friday, January 3rd, Jula Inrig sold 2,066 shares of Travere Therapeutics stock. The shares were sold at an average price of $19.10, for a total value of $39,460.60.

Travere Therapeutics Price Performance

TVTX stock opened at $21.10 on Wednesday. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $21.56. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The firm has a 50 day moving average of $18.69 and a 200 day moving average of $15.47.

Wall Street Analyst Weigh In

A number of research analysts have commented on TVTX shares. HC Wainwright raised their target price on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Cantor Fitzgerald assumed coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating on the stock. Scotiabank upped their target price on Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Bank of America boosted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Finally, Barclays lifted their target price on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TVTX. R Squared Ltd acquired a new position in shares of Travere Therapeutics in the fourth quarter valued at about $53,000. CWM LLC boosted its holdings in shares of Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after acquiring an additional 3,065 shares during the last quarter. Quarry LP acquired a new stake in shares of Travere Therapeutics in the third quarter worth $105,000. Sei Investments Co. purchased a new position in shares of Travere Therapeutics during the second quarter worth $117,000. Finally, Diversified Trust Co purchased a new stake in Travere Therapeutics in the third quarter valued at $161,000.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.